$EYPT
EyePoint Pharmaceuticals, Inc.

2019 Q3 Form 10-Q Financial Statement

#000156459019029987 Filed on August 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q3
Revenue $2.509M $7.210M $486.0K
YoY Change 416.26% 908.39% 26.23%
Cost Of Revenue $330.0K $706.0K
YoY Change
Gross Profit $2.180M $6.504M
YoY Change 809.65%
Gross Profit Margin 86.89% 90.21%
Selling, General & Admin $12.14M $12.10M $7.807M
YoY Change 55.54% 111.08% 203.54%
% of Gross Profit 557.02% 186.02%
Research & Development $3.484M $3.955M $6.233M
YoY Change -44.1% -17.0% 63.21%
% of Gross Profit 159.82% 60.81%
Depreciation & Amortization $650.0K $650.0K $43.00K
YoY Change 1411.63% 0.0% 10.26%
% of Gross Profit 29.82% 9.99%
Operating Expenses $16.57M $17.38M $14.04M
YoY Change 18.01% 65.52% 119.68%
Operating Profit -$14.06M -$10.17M -$13.55M
YoY Change 3.73% 3.92% 125.67%
Interest Expense $1.770M $1.599M $815.0K
YoY Change 117.18% 122.08%
% of Operating Profit
Other Income/Expense, Net -$1.587M -$1.333M -$19.57M
YoY Change -91.89% -94.59% -85195.65%
Pretax Income -$15.65M -$11.50M -$33.13M
YoY Change -52.76% -66.6% 454.01%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$15.65M -$11.50M -$33.13M
YoY Change -52.77% -66.6% 453.67%
Net Earnings / Revenue -623.63% -159.47% -6816.05%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.464M -$1.083M -$4.406M
COMMON SHARES
Basic Shares Outstanding 106.3M 106.1M 74.51M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.80M $44.20M $55.80M
YoY Change -43.01% 13.92% 372.88%
Cash & Equivalents $31.76M $44.16M $55.76M
Short-Term Investments
Other Short-Term Assets $3.900M $3.100M $1.400M
YoY Change 178.57% 287.5% 250.0%
Inventory $2.559M $1.670M
Prepaid Expenses
Receivables $8.900M $9.600M $500.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $47.06M $58.57M $57.64M
YoY Change -18.36% 46.77% 359.41%
LONG-TERM ASSETS
Property, Plant & Equipment $386.0K $417.0K $320.0K
YoY Change 20.63% 64.82% -5.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% -33.33%
Total Long-Term Assets $32.01M $32.76M $31.21M
YoY Change 2.54% 3.14% 3901.67%
TOTAL ASSETS
Total Short-Term Assets $47.06M $58.57M $57.64M
Total Long-Term Assets $32.01M $32.76M $31.21M
Total Assets $79.07M $91.33M $88.86M
YoY Change -11.02% 27.43% 566.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.461M $6.066M $4.075M
YoY Change 34.01% 106.33% 132.06%
Accrued Expenses $4.446M $4.214M $3.343M
YoY Change 32.99% 13.19% 33.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.37M $10.72M $22.42M
YoY Change -53.75% -50.51% 423.91%
LONG-TERM LIABILITIES
Long-Term Debt $46.73M $46.25M $17.46M
YoY Change 167.61% 167.2%
Other Long-Term Liabilities $3.000M $3.000M $1.269M
YoY Change 136.41% 143.7%
Total Long-Term Liabilities $49.73M $49.25M $18.73M
YoY Change 165.5% 165.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.37M $10.72M $22.42M
Total Long-Term Liabilities $49.73M $49.25M $18.73M
Total Liabilities $63.13M $63.12M $41.15M
YoY Change 53.41% 5.23% 851.23%
SHAREHOLDERS EQUITY
Retained Earnings -$454.9M -$439.2M -$396.9M
YoY Change 14.61% 20.67% 25.28%
Common Stock $470.0M $466.6M $443.8M
YoY Change 5.91% 24.48% 36.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.94M $28.21M $47.71M
YoY Change
Total Liabilities & Shareholders Equity $79.07M $91.33M $88.86M
YoY Change -11.02% 27.43% 566.73%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q3
OPERATING ACTIVITIES
Net Income -$15.65M -$11.50M -$33.13M
YoY Change -52.77% -66.6% 453.67%
Depreciation, Depletion And Amortization $650.0K $650.0K $43.00K
YoY Change 1411.63% 0.0% 10.26%
Cash From Operating Activities -$14.77M -$17.11M -$11.77M
YoY Change 25.53% 181.41% 97.15%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$30.00K $109.0K
YoY Change -100.0% -40.0% 70.31%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$30.00K -$109.0K
YoY Change -100.0% -98.29% 70.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $28.90M
YoY Change 2901.04%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.370M 17.92M 28.86M
YoY Change -91.79% -40.78% 2897.2%
NET CHANGE
Cash From Operating Activities -14.77M -17.11M -11.77M
Cash From Investing Activities 0.000 -30.00K -109.0K
Cash From Financing Activities 2.370M 17.92M 28.86M
Net Change In Cash -12.40M 780.0K 16.99M
YoY Change -172.99% -96.52% -435.4%
FREE CASH FLOW
Cash From Operating Activities -$14.77M -$17.11M -$11.77M
Capital Expenditures $0.00 -$30.00K $109.0K
Free Cash Flow -$14.77M -$17.08M -$11.88M
YoY Change 24.38% 183.25% 96.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
dei Entity File Number
EntityFileNumber
000-51122
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
262774444
dei City Area Code
CityAreaCode
(617)
dei Local Phone Number
LocalPhoneNumber
926-5000
us-gaap Net Income Loss
NetIncomeLoss
-30736000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7753000
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7284000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8090000
CY2018Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1512000
eypt Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
1230000
eypt Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
0
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
17375000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
10497000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
974000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
11687000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9222000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1643000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44000
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-53000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40938000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14595000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4815000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7210000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
715000
dei Entity Address Address Line1
EntityAddressAddressLine1
480 Pleasant Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
445192000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-439229000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-408493000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
840000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Trading Symbol
TradingSymbol
EYPT
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
106297792
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44161000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45261000
CY2019Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
9598000
CY2018Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
627000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3144000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1434000
CY2019Q2 us-gaap Inventory Net
InventoryNet
1670000
CY2018Q4 us-gaap Inventory Net
InventoryNet
279000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
58573000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
47601000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
417000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
288000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3291000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28899000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
30129000
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2019Q2 us-gaap Assets
Assets
91330000
CY2018Q4 us-gaap Assets
Assets
78168000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6066000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2640000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4214000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3789000
CY2018Q4 eypt Accrued Development Milestone Current
AccruedDevelopmentMilestoneCurrent
15000000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
30000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
441000
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10721000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21459000
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
46250000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
17621000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3149000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3000000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1455000
CY2019Q2 us-gaap Liabilities
Liabilities
63120000
CY2018Q4 us-gaap Liabilities
Liabilities
40535000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
106000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
95000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
466493000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
46000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1100000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45411000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13026000
us-gaap Interest Paid Net
InterestPaidNet
1175000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
839000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1496000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
28210000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
37633000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91330000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78168000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
106297792
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95372236
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
106297792
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95372236
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
706000
CY2018Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1035000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3955000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4765000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1512000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4220000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9425000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6501000
CY2019Q2 eypt Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
615000
CY2018Q2 eypt Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
0
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55387000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
106238000
us-gaap Operating Expenses
OperatingExpenses
34038000
us-gaap Operating Expenses
OperatingExpenses
16103000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10165000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9782000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24816000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14460000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
266000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
27000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
509000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
52000
CY2019Q2 us-gaap Interest Expense
InterestExpense
1599000
CY2018Q2 us-gaap Interest Expense
InterestExpense
720000
us-gaap Interest Expense
InterestExpense
2619000
us-gaap Interest Expense
InterestExpense
720000
CY2018Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3810000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2018Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-23953000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-26278000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1333000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24646000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5920000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26946000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-11498000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-34428000
us-gaap Net Income Loss
NetIncomeLoss
-41406000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.82
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100847000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50542000
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2018Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11497000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34427000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30735000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41404000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
8198000
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1000
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36377000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
87000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
503000
CY2018Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-25000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
19877000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18343000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
355000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18343000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
308000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-73000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2734000
us-gaap Profit Loss
ProfitLoss
-30736000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1230000
us-gaap Depreciation
Depreciation
78000
eypt Amortization Of Debt Discount
AmortizationOfDebtDiscount
270000
us-gaap Paid In Kind Interest
PaidInKindInterest
406000
us-gaap Share Based Compensation
ShareBasedCompensation
2734000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
10681000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1392000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3826000
eypt Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
44000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-30000
eypt Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-11000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30441000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
207000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-207000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18343000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
50000000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
20000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1341000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1347000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
20000000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
2716000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
308000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
503000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
15000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29548000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53627000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
25900000
us-gaap Interest Paid Net
InterestPaidNet
258000
eypt Non Cash Accrued Development Milestone
NonCashAccruedDevelopmentMilestone
15000000
eypt Debt Instrument Exit Fee
DebtInstrumentExitFee
3000000
eypt Debt Instrument Exit Fee
DebtInstrumentExitFee
1200000
CY2019Q2 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1051000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1998000
eypt Fair Value Of Second Tranche Purchase Liability
FairValueOfSecondTranchePurchaseLiability
4734000
eypt Fair Value Of Warrants Issued With Debt
FairValueOfWarrantsIssuedWithDebt
355000
eypt Fair Value Of Second Tranche Warrants
FairValueOfSecondTrancheWarrants
18165000
us-gaap Nature Of Operations
NatureOfOperations
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:5.24%;white-space:nowrap"> <p style="margin-top:10pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-top:10pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Operations and Basis of Presentation&#160;&#160;</p></td></tr></table></div> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements of EyePoint Pharmaceuticals, Inc. and subsidiaries (collectively, the &#8220;Company&#8221;) as of June 30, 2019 and for the three and six months ended June 30, 2019 and 2018 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). These financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and footnotes included in the Company&#8217;s Transition Report on Form 10-K for the six months ended December 31, 2018. In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the six months ended December 31, 2018, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company&#8217;s financial position, results of operations, comprehensive loss and cash flows for the periods indicated. The preparation of financial statements in accordance with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.</p> <p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of eye diseases. <font style="Background-color:#FFFFFF;color:#000000;">The Company has two products, YUTIQ</font><font style="color:#000000;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font><font style="Background-color:#FFFFFF;color:#000000;"> and DEXYCU</font><font style="color:#000000;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font><font style="Background-color:#FFFFFF;color:#000000;">, which were approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in October 2018 and February 2018, respectively.</font></p> <p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, was launched directly in the U.S. in February 2019. YUTIQ is indicated for the treatment of chronic </font>non-infectious<font style="Background-color:#FFFFFF;"> uveitis affecting the posterior segment of the eye, which affects between 55,000 to 120,000 people in the U.S. each year and causes approximately 30,000 new cases of blindness every year, making it the third leading cause of blindness. Injected into the eye in an office visit, YUTIQ is a micro-insert that delivers a micro-dose of a corticosteroid to the back of the eye on a sustained constant (zero order release) basis for up to 36 months. YUTIQ is based on the Company&#8217;s proprietary Durasert&#8482; sustained-release drug delivery technology platform, which can deliver drugs for predetermined periods of time ranging from months to years.</font></p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">DEXYCU (dexamethasone intraocular suspension) 9%, </font>for intraocular administration, was launched directly in the U.S. in March 2019. Indicated for the treatment of post-operative ocular inflammation, DEXYCU <font style="Background-color:#FFFFFF;">is administered as a single dose at the end of ocular surgery and is the first long-acting intraocular product approved by the FDA for this indication. DEXYCU utilizes the Company&#8217;s proprietary Verisome</font><sup style="font-size:85%; vertical-align:top">&#174;</sup><font style="Background-color:#FFFFFF;"> drug-delivery platform, which allows for a single intraocular injection that releases dexamethasone, a corticosteroid, over time. There were approximately 4.8&#160;million cataract surgeries performed during 2018 in the U.S., with growth projected at an estimated annual rate of 8%, and the Company launched DEXYCU with a primary focus on its use following cataract surgery. The Company acquired DEXYCU in connection with its acquisition of Icon Bioscience, Inc. (&#8220;Icon&#8221;) in March 2018. </font></p> <p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ILUVIEN<sup style="font-size:85%; vertical-align:top">&#174;</sup>&#160;for diabetic macular edema (&#8220;DME&#8221;), the Company&#8217;s lead licensed product, is sold directly in the U.S. and several European Union (&#8220;EU&#8221;) countries by Alimera Sciences, Inc. (&#8220;Alimera&#8221;). In July 2017, the Company expanded its license agreement with Alimera to include the uveitis indication utilizing the Durasert technology in Europe, the Middle East and Africa (&#8220;EMEA&#8221;), which received European regulatory approval in March 2019 and, subject to obtaining pricing and reimbursement in each applicable country, will be marketed as ILUVIEN. Retisert<sup style="font-size:85%; vertical-align:top">&#174;</sup>, one of the Company&#8217;s earlier generation products, was approved in 2005 by the FDA for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye and is sold in the U.S. by Bausch &amp; Lomb Inc. (&#8220;Bausch &amp; Lomb&#8221;). The Company&#8217;s development programs are focused primarily on developing sustained release products that utilize its Durasert and Verisome technology platforms to deliver approved drugs to treat chronic diseases. The Company&#8217;s strategy includes developing products independently while continuing to leverage its technology platforms through collaborations and license agreements.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company has a history of operating losses and has not had significant recurring cash inflows from revenue.</font><font style="color:#000000;"> The Company&#8217;s operations have been financed primarily from sales of its equity securities, issuance of debt and a combination of royalty income and other fees received from collaboration partners</font><font style="Background-color:#FFFFFF;">. In April 2019, t</font><font style="color:#000000;">he Company consummated an equity offering of its common stock (&#8220;Common Stock&#8221;), resulting in net proceeds of approximately $18.3 million. During April 2019, the Company exercised its option to draw an additional $15.0 million under the new term loan agreement (the &#8220;CRG Loan Agreement&#8221;) with CRG Servicing LLC&nbsp;&nbsp;(&#8220;CRG&#8221;) and paid a $15.0 million development milestone that was due to the former Icon security holders following the first commercial sale of DEXYCU (see Note 3). The Company had cash and cash equivalents of $44.2 million at June 30, 2019&#160;.</font></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2019, the Company commenced the U.S. launch of its first two commercial products, YUTIQ and DEXYCU. Overall, the commercial launch of YUTIQ and DEXYCU has been encouraging with demand for YUTIQ exceeding the Company&#8217;s expectations. Interest in DEXYCU remains strong within the physician groups that have received training and are now authorized to order DEXYCU from their wholesalers, and DEXYCU demand within these groups have been increasing during the second quarter of 2019. However, overall DEXYCU demand has been slower than anticipated due in part to Ambulatory Surgical Centers&#8217; office management generally adopting a cautious approach to the reimbursement process, as reimbursement for other surgical drugs has been inconsistent in the past. Even though DEXYCU has a &#8220;J&#8221; code which should enable a more straightforward and consistent reimbursement process, particularly when patients are covered by commercial and Medicare Advantage plans, many Ambulatory Surgical Centers nevertheless are waiting to ensure reimbursement of DEXYCU across multiple insurers before ordering the product in significant volume. Additionally, physicians have been utilizing the Company&#8217;s non-revenue sample program to facilitate their training. These factors have contributed to a reduced anticipated cash flow from the early launch of DEXYCU. The Company expects that its existing cash and cash equivalents at June 30, 2019 and cash inflows from anticipated YUTIQ and DEXYCU product sales will be sufficient to fund the Company&#8217;s operating plan into 2020.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company, however, has no history of direct commercialization of its products and management does not yet have sufficient historical evidence to assert that it is probable that the Company will receive sufficient revenues from its sales of YUTIQ and DEXYCU to fund operations. Actual cash requirements could differ from management&#8217;s projections due to many factors, including the success of commercialization for YUTIQ and DEXYCU, the actual costs of these commercialization efforts, additional investments in research and development programs, competing technological and market developments and the costs of any strategic acquisitions and/or development of complementary business opportunities. Accordingly, the foregoing conditions, taken together, continue to raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year from the issuance of these financial statements.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted and Recently Issued Accounting Pronouncements</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted accounting pronouncements will not have a material impact on the Company&#8217;s financial position, results of operations and cash flows or do not apply to the Company&#8217;s operations.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, <font style="font-style:italic;">Leases</font> (<font style="font-style:italic;">Topic 842</font>) (&#8220;ASU 2016-02&#8221;). <font style="color:#000000;">In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842), Targeted Improvements, which contains certain amendments to ASU 2016-02 intended to provide relief in implementing the new standard. </font>The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all operating leases, with an exception provided for leases with a duration of one year or less. The Company adopted ASU 2016-02 on January 1, 2019 using the modified retrospective transition approach which, pursuant to ASU 2018-11, allows companies to recognize existing<font style="color:#000000;"> leases at the adoption date without requiring comparable period presentation. Comparative periods are presented in accordance with the previous guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 840, Leases.</font></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In adopting the new standard, the Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company elected to combine lease and non-lease components and to exclude leases with a term of 12 months or less. The adoption of this accounting standard resulted in recording operating lease ROU assets for three real estate operating lease arrangements and corresponding operating lease liabilities of $3.5 million and $3.7 million, respectively, as of January 1, 2019. The operating lease assets at adoption were lower than the operating lease liabilities because the balance of the Company&#8217;s deferred rent liabilities at December 31, 2018, which represented lease incentives, was reclassified into operating lease assets. The adoption of the standard did not have a material effect on the Company&#8217;s consolidated statements of operations or consolidated statements of cash flows.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Topic 842, the Company determines whether the arrangement is or contains a lease at inception. Operating leases are recognized on the consolidated balance sheets as ROU assets, current portion of lease liabilities and long-term lease liabilities. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. <font style="color:#000000;">For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. </font>The operating lease ROU assets also include any lease payments made and adjustments for prepayments and lease incentives. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilized its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <font style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</font> to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2018. This standard will be effective for the Company in the first quarter of its fiscal year ending December 31, 2020. The Company is<font style="color:#000000;"> currently evaluating the impact the adoption of this update will have on its consolidated financial statements.</font></p>
CY2019Q2 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
554000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
849000
CY2018Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
36964000
CY2018Q4 eypt Operating Leases Future Minimum Payments Due In Year Five And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInYearFiveAndThereafter
1990000
CY2018Q4 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
798000
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
400000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
5439000
CY2019Q2 eypt Accrued Development Milestone Current
AccruedDevelopmentMilestoneCurrent
15000000
CY2018Q1 eypt Percentage Of Partnering Income Received Payable As Earnout Consideration
PercentageOfPartneringIncomeReceivedPayableAsEarnoutConsideration
0.20
CY2018Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
36349000
us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
0
us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
31973000
CY2019Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2018Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
38193000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
36349000
CY2019Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
39423000
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
31358000
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
615000
CY2018Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
615000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13717898
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2066000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30321078
CY2018Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
0
eypt Contract With Customer Allowance For Credit Loss Reduction
ContractWithCustomerAllowanceForCreditLossReduction
-89000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
895000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
571000
CY2019Q2 eypt Product Revenue Allowances And Reserves Current
ProductRevenueAllowancesAndReservesCurrent
1051000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
143000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
422000
us-gaap Line Of Credit Facility Expiration Period
LineOfCreditFacilityExpirationPeriod
P5Y
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M12D
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.125
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
425000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
867000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
889000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
849000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
815000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1176000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5021000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1431000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3590000
CY2019Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
213000
us-gaap Operating Lease Expense
OperatingLeaseExpense
427000
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
9000
us-gaap Variable Lease Cost
VariableLeaseCost
18000
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
205000
us-gaap Operating Lease Payments
OperatingLeasePayments
383000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
826000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
879000
eypt Contract With Customer Allowance For Credit Loss Additions
ContractWithCustomerAllowanceForCreditLossAdditions
1140000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
486812
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
eypt Warrants Issued In Connection With Term Loan Facility
WarrantsIssuedInConnectionWithTermLoanFacility
0
eypt Warrants Issued In Connection With Term Loan Facility
WarrantsIssuedInConnectionWithTermLoanFacility
486812
CY2019Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
486812
CY2018Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
486812
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.23
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0
eypt Exercise Price Of Issued Warrants
ExercisePriceOfIssuedWarrants
0
eypt Exercise Price Of Issued Warrants
ExercisePriceOfIssuedWarrants
1.23
CY2019Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.23
CY2018Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.23
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1417000
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6000000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
eypt Remeasurement Of Second Tranche Transaction Liability To Fair Value Description
RemeasurementOfSecondTrancheTransactionLiabilityToFairValueDescription
This valuation at settlement was calculated as the excess of the sum of (i) the fair value of the Second Tranche Warrants and (ii) the fair value of the shares of Common Stock issued to settle the liability over the cash proceeds received by the Company for the Units.
CY2018Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28900000
eypt Transaction Costs Allocated To Derivative Liabilities Expensed As Change In Fair Value Of Derivative
TransactionCostsAllocatedToDerivativeLiabilitiesExpensedAsChangeInFairValueOfDerivative
326000
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30321078
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13717898

Files In Submission

Name View Source Status
0001564590-19-029987-index-headers.html Edgar Link pending
0001564590-19-029987-index.html Edgar Link pending
0001564590-19-029987.txt Edgar Link pending
0001564590-19-029987-xbrl.zip Edgar Link pending
eypt-10q_20190630.htm Edgar Link pending
eypt-20190630.xml Edgar Link completed
eypt-20190630.xsd Edgar Link pending
eypt-20190630_cal.xml Edgar Link unprocessable
eypt-20190630_def.xml Edgar Link unprocessable
eypt-20190630_lab.xml Edgar Link unprocessable
eypt-20190630_pre.xml Edgar Link unprocessable
eypt-ex104_247.htm Edgar Link pending
eypt-ex105_518.htm Edgar Link pending
eypt-ex311_9.htm Edgar Link pending
eypt-ex312_8.htm Edgar Link pending
eypt-ex321_6.htm Edgar Link pending
eypt-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g0n3btqsdsjz000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending